The outcomes reported in Fig. 3 seem to support a RAPA-mediated delay of disease progression in dystroglycanopathy muscle. This evidence concerns the gene TRERF1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.